Comparison of next‑generation sequencing quality metrics and concordance in the detection of cancer‑specific molecular alterations between formalin‑fixed paraffin‑embedded and fresh‑frozen samples in comprehensive genomic profiling with the Illumina®

Next-generation sequencing (NGS) technology is routinely employed to detect clinically significant variants in the field of precision medicine. Formalin-fixed paraffin-embedded (FFPE) tissues remain a widely used source of genetic material for diagnostic purposes due to their long-term storage stability, which preserves the architecture of tumour tissues. However, the degradation of nucleic acids (NAs) that occurs during the fixation process can lead to unreliable results or hinder analysis. Considering the challenges posed by the quality and quantity of nucleic acids extracted from FFPE samples, the present study aimed to compare paired fresh-frozen (FF) and FFPE samples. The present study also aimed to assess the concordance rate of quality control metrics of sequenced libraries and identify variants and biomarkers between FFPE and FF tissues. The Illumina<sup>®</sup> TruSight Oncology 500 assay (TSO 500; Illumina, Inc.) was used to conduct comprehensive genomic profiling of samples from patients with various cancer types. All identified alterations were annotated using the Pierian Dx Clinical Genomics Workspace version 6.20 (PierianDx CGW). A total of 138 DNA and 138 RNA analyses on 69 paired samples were performed. These results demonstrated the significant potential of FF tissue as a primary source of higher-quality genetic material to detect small variants, microsatellite instabilities and the tumour mutational burden, using the TSO 500 assay compared with FFPE samples. This approach could effectively reduce the issues associated with poor-quality NAs extracted from FFPE samples. Based on our findings of lower concordance in the detection of splice variants, fusions and copy number variants in paired samples, we recommend that future studies using the TSO 500 assay should focus directly on this issue.

Authors

Institutions

Publication Details

Journal
Experimental and Therapeutic Medicine
Published
2025-02-04
DOI
https://doi.org/10.3892/etm.2025.12814
Citations
1
Primary Topic
Molecular Biology Techniques and Applications
Type
article
Field-Weighted Citation Impact
0.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparison of next‑generation sequencing quality metrics and concordance in the detection of cancer‑specific molecular alterations between formalin‑fixed paraffin‑embedded and fresh‑frozen samples in comprehensive genomic profiling with the Illumina®

Anton Dzian, Katarína Tobiášová, Dušan Loderer, Andrea Horňáková et al.
1 citations
Experimental and Therapeutic Medicine
Molecular Biology Techniques and Applications
0.81
article

Comparison of next‑generation sequencing quality metrics and concordance in the detection of cancer‑specific molecular alterations between formalin‑fixed paraffin‑embedded and fresh‑frozen samples in comprehensive genomic profiling with the Illumina®

Anton Dzian, Katarína Tobiášová, Dušan Loderer, Andrea Horňáková, Peter Mikolajčík, Zuzana Daňková, Marek Smolár, Tomáš Rokos, Juraj Miklušica, Kamil Biringer, Marian Grendár, Lukáš Plank, Erika Halášová, Erik Kúdela, Katarína Lešková
article en
1 citations

Abstract

Next-generation sequencing (NGS) technology is routinely employed to detect clinically significant variants in the field of precision medicine. Formalin-fixed paraffin-embedded (FFPE) tissues remain a widely used source of genetic material for diagnostic purposes due to their long-term storage stability, which preserves the architecture of tumour tissues. However, the degradation of nucleic acids (NAs) that occurs during the fixation process can lead to unreliable results or hinder analysis. Considering the challenges posed by the quality and quantity of nucleic acids extracted from FFPE samples, the present study aimed to compare paired fresh-frozen (FF) and FFPE samples. The present study also aimed to assess the concordance rate of quality control metrics of sequenced libraries and identify variants and biomarkers between FFPE and FF tissues. The Illumina<sup>®</sup> TruSight Oncology 500 assay (TSO 500; Illumina, Inc.) was used to conduct comprehensive genomic profiling of samples from patients with various cancer types. All identified alterations were annotated using the Pierian Dx Clinical Genomics Workspace version 6.20 (PierianDx CGW). A total of 138 DNA and 138 RNA analyses on 69 paired samples were performed. These results demonstrated the significant potential of FF tissue as a primary source of higher-quality genetic material to detect small variants, microsatellite instabilities and the tumour mutational burden, using the TSO 500 assay compared with FFPE samples. This approach could effectively reduce the issues associated with poor-quality NAs extracted from FFPE samples. Based on our findings of lower concordance in the detection of splice variants, fusions and copy number variants in paired samples, we recommend that future studies using the TSO 500 assay should focus directly on this issue.

Experimental and Therapeutic MedicineVol. 29(4)
Comenius University Bratislava (SK)
European Regional Development Fund
Zero hunger
Openalex Percentile: Top 31%
Molecular Biology Techniques and Applications
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.